{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T09:46:54Z","timestamp":1779356814139,"version":"3.51.4"},"reference-count":167,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s12035-025-04720-z","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T22:16:41Z","timestamp":1738361801000},"page":"7393-7412","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Role of \u0394FosB in the Pathogenesis of Levodopa-Induced Dyskinesia: Mechanisms and Therapeutic Strategies"],"prefix":"10.1007","volume":"62","author":[{"given":"Mohammad Yasin","family":"Zamanian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Kamran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marziye Ranjbar","family":"Tavakoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enwa Felix","family":"Oghenemaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Abohassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aziz","family":"Kubaev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Nathiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parjinder","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Hussein","family":"Zwamel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Resan Shakir","family":"Abdulamer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"issue":"23","key":"4720_CR1","doi-asserted-by":"publisher","first-page":"3736","DOI":"10.3390\/cells11233736","volume":"11","author":"DK Kwon","year":"2022","unstructured":"Kwon DK et al (2022) Levodopa-induced dyskinesia in Parkinson\u2019s disease: pathogenesis and emerging treatment strategies. Cells 11(23):3736","journal-title":"Cells"},{"key":"4720_CR2","doi-asserted-by":"publisher","first-page":"111125","DOI":"10.1016\/j.cellsig.2024.111125","volume":"118","author":"K Liu","year":"2024","unstructured":"Liu K et al (2024) AMPK-mediated autophagy pathway activation promotes \u0394FosB degradation to improve levodopa-induced dyskinesia. Cell Signal 118:111125","journal-title":"Cell Signal"},{"key":"4720_CR3","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s12640-018-9993-0","volume":"35","author":"V Palafox-Sanchez","year":"2019","unstructured":"Palafox-Sanchez V et al (2019) Differential expression of striatal \u0394FosB mRNA and FosB mRNA after different levodopa treatment regimens in a rat model of Parkinson\u2019s disease. Neurotox Res 35:563\u2013574","journal-title":"Neurotox Res"},{"issue":"21","key":"4720_CR4","doi-asserted-by":"publisher","first-page":"7335","DOI":"10.1523\/JNEUROSCI.0252-10.2010","volume":"30","author":"X Cao","year":"2010","unstructured":"Cao X et al (2010) Striatal overexpression of \u0394FosB reproduces chronic levodopa-induced involuntary movements. J Neurosci 30(21):7335\u20137343","journal-title":"J Neurosci"},{"issue":"2","key":"4720_CR5","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.molbrainres.2004.05.014","volume":"132","author":"CA McClung","year":"2004","unstructured":"McClung CA et al (2004) \u0394FosB: a molecular switch for long-term adaptation in the brain. Mol Brain Res 132(2):146\u2013154","journal-title":"Mol Brain Res"},{"issue":"1","key":"4720_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/S0006-8993(98)01191-3","volume":"835","author":"EJ Nestler","year":"1999","unstructured":"Nestler EJ, Kelz MB, Chen J (1999) \u0394FosB: a molecular mediator of long-term neural and behavioral plasticity. Brain Res 835(1):10\u201317","journal-title":"Brain Res"},{"issue":"5","key":"4720_CR7","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.biopsych.2014.07.007","volume":"79","author":"M Engeln","year":"2016","unstructured":"Engeln M et al (2016) Selective inactivation of striatal FosB\/\u0394FosB-expressing neurons alleviates L-DOPA\u2013induced dyskinesia. Biol Psychiat 79(5):354\u2013361","journal-title":"Biol Psychiat"},{"issue":"1","key":"4720_CR8","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.biopsych.2005.05.044","volume":"59","author":"N Pav\u00f3n","year":"2006","unstructured":"Pav\u00f3n N et al (2006) ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiat 59(1):64\u201374","journal-title":"Biol Psychiat"},{"issue":"10","key":"4720_CR9","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1111\/j.1460-9568.2007.05575.x","volume":"25","author":"TL Carle","year":"2007","unstructured":"Carle TL et al (2007) Proteasome-dependent and-independent mechanisms for FosB destabilization: identification of FosB degron domains and implications for \u0394FosB stability. Eur J Neurosci 25(10):3009\u20133019","journal-title":"Eur J Neurosci"},{"issue":"37","key":"4720_CR10","doi-asserted-by":"publisher","first-page":"18664","DOI":"10.1073\/pnas.1907810116","volume":"116","author":"G Beck","year":"2019","unstructured":"Beck G et al (2019) Role of striatal \u0394FosB in L-Dopa\u2013induced dyskinesias of parkinsonian nonhuman primates. Proc Natl Acad Sci 116(37):18664\u201318672","journal-title":"Proc Natl Acad Sci"},{"key":"4720_CR11","doi-asserted-by":"publisher","first-page":"113327","DOI":"10.1016\/j.expneurol.2020.113327","volume":"330","author":"K Steece-Collier","year":"2020","unstructured":"Steece-Collier K et al (2020) Striatal Nurr1, but not FosB expression links a levodopa-induced dyskinesia phenotype to genotype in Fisher 344 vs. Lewis hemiparkinsonian rats. Exp Neurol 330:113327","journal-title":"Exp Neurol"},{"issue":"6","key":"4720_CR12","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.biopsych.2009.04.025","volume":"66","author":"S Darmopil","year":"2009","unstructured":"Darmopil S et al (2009) Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA\u2013induced dyskinesia and histone activation. Biol Psychiat 66(6):603\u2013613","journal-title":"Biol Psychiat"},{"issue":"5","key":"4720_CR13","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.biopsych.2014.07.019","volume":"79","author":"M Feyder","year":"2016","unstructured":"Feyder M et al (2016) A role for mitogen-and stress-activated kinase 1 in L-DOPA\u2013induced dyskinesia and\u2206 FosB expression. Biol Psychiat 79(5):362\u2013371","journal-title":"Biol Psychiat"},{"issue":"50","key":"4720_CR14","doi-asserted-by":"publisher","first-page":"21824","DOI":"10.1073\/pnas.1012071107","volume":"107","author":"S Fasano","year":"2010","unstructured":"Fasano S et al (2010) Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa\u2013induced dyskinesia. Proc Natl Acad Sci 107(50):21824\u201321829","journal-title":"Proc Natl Acad Sci"},{"key":"4720_CR15","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3389\/fnins.2017.00112","volume":"11","author":"G Chen","year":"2017","unstructured":"Chen G et al (2017) Antidyskinetic effects of MEK inhibitor are associated with multiple neurochemical alterations in the striatum of hemiparkinsonian rats. Front Neurosci 11:112","journal-title":"Front Neurosci"},{"issue":"1","key":"4720_CR16","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.nbd.2009.12.027","volume":"38","author":"M Lebel","year":"2010","unstructured":"Lebel M et al (2010) Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat. Neurobiol Dis 38(1):59\u201367","journal-title":"Neurobiol Dis"},{"key":"4720_CR17","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.neurobiolaging.2019.06.004","volume":"81","author":"MR Ahmed","year":"2019","unstructured":"Ahmed MR et al (2019) Pharmacological antagonism of histamine H2R ameliorated L-DOPA-induced dyskinesia via normalization of GRK3 and by suppressing FosB and ERK in PD. Neurobiol Aging 81:177\u2013189","journal-title":"Neurobiol Aging"},{"key":"4720_CR18","first-page":"105","volume":"10","author":"Q Wang","year":"2016","unstructured":"Wang Q, Zhang W (2016) Maladaptive synaptic plasticity in L-DOPA-induced dyskinesia. Front Neural Circ 10:105","journal-title":"Front Neural Circ"},{"issue":"6","key":"4720_CR19","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.biopsych.2009.04.005","volume":"66","author":"O Berton","year":"2009","unstructured":"Berton O et al (2009) Striatal overexpression of \u0394JunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease. Biol Psychiat 66(6):554\u2013561","journal-title":"Biol Psychiat"},{"issue":"6","key":"4720_CR20","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1006\/nbdi.1999.0259","volume":"6","author":"M Andersson","year":"1999","unstructured":"Andersson M, Hilbertson A, Cenci M (1999) Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson\u2019s disease. Neurobiol Dis 6(6):461\u2013474","journal-title":"Neurobiol Dis"},{"issue":"6","key":"4720_CR21","doi-asserted-by":"publisher","first-page":"5125","DOI":"10.1007\/s12035-017-0748-3","volume":"55","author":"S Sanz-Blasco","year":"2018","unstructured":"Sanz-Blasco S et al (2018) The kinase fyn as a novel intermediate in L-DOPA-induced dyskinesia in Parkinson\u2019s disease. Mol Neurobiol 55(6):5125\u20135136","journal-title":"Mol Neurobiol"},{"issue":"11","key":"4720_CR22","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1523\/JNEUROSCI.5326-05.2006","volume":"26","author":"F Gardoni","year":"2006","unstructured":"Gardoni F et al (2006) A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. J Neurosci 26(11):2914\u20132922","journal-title":"J Neurosci"},{"issue":"5","key":"4720_CR23","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1021\/cn400016d","volume":"4","author":"OS Mabrouk","year":"2013","unstructured":"Mabrouk OS et al (2013) GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats. ACS Chem Neurosci 4(5):808\u2013816","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"4720_CR24","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41531-023-00586-x","volume":"9","author":"M L\u00f3pez-Aguirre","year":"2023","unstructured":"L\u00f3pez-Aguirre M et al (2023) Dopaminergic denervation and associated MRI microstructural changes in the nigrostriatal projection in early Parkinson\u2019s disease patients. npg Parkinson\u2019s Dis 9(1):144","journal-title":"npg Parkinson\u2019s Dis"},{"issue":"3","key":"4720_CR25","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1523\/JNEUROSCI.1690-21.2021","volume":"42","author":"J Fooken","year":"2022","unstructured":"Fooken J et al (2022) Preservation of eye movements in Parkinson\u2019s disease is stimulus-and task-specific. J Neurosci 42(3):487\u2013499","journal-title":"J Neurosci"},{"issue":"10","key":"4720_CR26","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.3390\/biom11101508","volume":"11","author":"A Picca","year":"2021","unstructured":"Picca A et al (2021) Mitochondrial dysfunction, protein misfolding and neuroinflammation in Parkinson\u2019s disease: roads to biomarker discovery. Biomolecules 11(10):1508","journal-title":"Biomolecules"},{"key":"4720_CR27","doi-asserted-by":"publisher","unstructured":"Serratos IN, et al (2022) An update on the critical role of \u03b1-synuclein in Parkinson\u2019s disease and other synucleinopathies: from tissue to cellular and molecular levels. Mol Neurobiol 1\u201323. https:\/\/doi.org\/10.1007\/s12035-021-02596-3","DOI":"10.1007\/s12035-021-02596-3"},{"issue":"4","key":"4720_CR28","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.tibs.2020.11.007","volume":"46","author":"AB Malpartida","year":"2021","unstructured":"Malpartida AB et al (2021) Mitochondrial dysfunction and mitophagy in Parkinson\u2019s disease: from mechanism to therapy. Trends Biochem Sci 46(4):329\u2013343","journal-title":"Trends Biochem Sci"},{"issue":"1","key":"4720_CR29","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1080\/13880209.2016.1244553","volume":"55","author":"M Zamanian","year":"2017","unstructured":"Zamanian M et al (2017) Effects of naringin on physical fatigue and serum MMP-9 concentration in female rats. Pharm Biol 55(1):423\u2013427","journal-title":"Pharm Biol"},{"issue":"9","key":"4720_CR30","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1002\/glia.24385","volume":"71","author":"SM Rocha","year":"2023","unstructured":"Rocha SM et al (2023) Microglia-specific knock-out of NF-\u03baB\/IKK2 increases the accumulation of misfolded \u03b1-synuclein through the inhibition of p62\/sequestosome-1-dependent autophagy in the rotenone model of Parkinson\u2019s disease. Glia 71(9):2154\u20132179","journal-title":"Glia"},{"issue":"1","key":"4720_CR31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/bph.15684","volume":"179","author":"ME Haque","year":"2022","unstructured":"Haque ME et al (2022) Targeting \u03b1-synuclein aggregation and its role in mitochondrial dysfunction in Parkinson\u2019s disease. Br J Pharmacol 179(1):23\u201345","journal-title":"Br J Pharmacol"},{"issue":"5","key":"4720_CR32","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3390\/biom11050718","volume":"11","author":"P Risiglione","year":"2021","unstructured":"Risiglione P et al (2021) Alpha-synuclein and mitochondrial dysfunction in Parkinson\u2019s disease: the emerging role of VDAC. Biomolecules 11(5):718","journal-title":"Biomolecules"},{"issue":"7","key":"4720_CR33","doi-asserted-by":"publisher","first-page":"e1820","DOI":"10.1038\/cddis.2015.166","volume":"6","author":"A Reeve","year":"2015","unstructured":"Reeve A et al (2015) Aggregated \u03b1-synuclein and complex I deficiency: exploration of their relationship in differentiated neurons. Cell Death Dis 6(7):e1820\u2013e1820","journal-title":"Cell Death Dis"},{"key":"4720_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-019-0349-x","volume":"15","author":"J-H Park","year":"2020","unstructured":"Park J-H et al (2020) Alpha-synuclein-induced mitochondrial dysfunction is mediated via a sirtuin 3-dependent pathway. Mol Neurodegener 15:1\u201319","journal-title":"Mol Neurodegener"},{"issue":"2","key":"4720_CR35","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41419-021-03441-0","volume":"12","author":"M Bi","year":"2021","unstructured":"Bi M et al (2021) Expanding the role of proteasome homeostasis in Parkinson\u2019s disease: beyond protein breakdown. Cell Death Dis 12(2):154","journal-title":"Cell Death Dis"},{"issue":"9","key":"4720_CR36","doi-asserted-by":"publisher","first-page":"4676","DOI":"10.3390\/ijms22094676","volume":"22","author":"K Badanjak","year":"2021","unstructured":"Badanjak K et al (2021) The contribution of microglia to neuroinflammation in Parkinson\u2019s disease. Int J Mol Sci 22(9):4676","journal-title":"Int J Mol Sci"},{"key":"4720_CR37","doi-asserted-by":"publisher","first-page":"105654","DOI":"10.1016\/j.nbd.2022.105654","volume":"166","author":"A Kasen","year":"2022","unstructured":"Kasen A et al (2022) Upregulation of \u03b1-synuclein following immune activation: possible trigger of Parkinson\u2019s disease. Neurobiol Dis 166:105654","journal-title":"Neurobiol Dis"},{"issue":"22","key":"4720_CR38","doi-asserted-by":"publisher","first-page":"8421","DOI":"10.3390\/ijms21228421","volume":"21","author":"C Marogianni","year":"2020","unstructured":"Marogianni C et al (2020) Neurodegeneration and inflammation\u2014an interesting interplay in Parkinson\u2019s disease. Int J Mol Sci 21(22):8421","journal-title":"Int J Mol Sci"},{"key":"4720_CR39","doi-asserted-by":"publisher","first-page":"661838","DOI":"10.3389\/fncel.2021.661838","volume":"15","author":"F Takata","year":"2021","unstructured":"Takata F et al (2021) Blood-brain barrier dysfunction amplifies the development of neuroinflammation: understanding of cellular events in brain microvascular endothelial cells for prevention and treatment of BBB dysfunction. Front Cell Neurosci 15:661838","journal-title":"Front Cell Neurosci"},{"issue":"3","key":"4720_CR40","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jphs.2020.07.011","volume":"144","author":"L Iovino","year":"2020","unstructured":"Iovino L, Tremblay M, Civiero L (2020) Glutamate-induced excitotoxicity in Parkinson\u2019s disease: the role of glial cells. J Pharmacol Sci 144(3):151\u2013164","journal-title":"J Pharmacol Sci"},{"issue":"8","key":"4720_CR41","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3390\/antiox9080743","volume":"9","author":"DS Simpson","year":"2020","unstructured":"Simpson DS, Oliver PL (2020) ROS generation in microglia: understanding oxidative stress and inflammation in neurodegenerative disease. Antioxidants 9(8):743","journal-title":"Antioxidants"},{"issue":"24","key":"4720_CR42","doi-asserted-by":"publisher","first-page":"13315","DOI":"10.3390\/ijms222413315","volume":"22","author":"KH Lee","year":"2021","unstructured":"Lee KH, Cha M, Lee BH (2021) Crosstalk between neuron and glial cells in oxidative injury and neuroprotection. Int J Mol Sci 22(24):13315","journal-title":"Int J Mol Sci"},{"issue":"5","key":"4720_CR43","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1177\/1073858421992265","volume":"28","author":"SY Lee","year":"2022","unstructured":"Lee SY, Yates NJ, Tye SJ (2022) Inflammatory mechanisms in Parkinson\u2019s disease: from pathogenesis to targeted therapies. Neuroscientist 28(5):485\u2013506","journal-title":"Neuroscientist"},{"issue":"7","key":"4720_CR44","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.3390\/cells9071687","volume":"9","author":"M Pajares","year":"2020","unstructured":"Pajares M et al (2020) Inflammation in Parkinson\u2019s disease: mechanisms and therapeutic implications. Cells 9(7):1687","journal-title":"Cells"},{"issue":"2\u20133","key":"4720_CR45","first-page":"55","volume":"20","author":"S He","year":"2021","unstructured":"He S et al (2021) Alpha-synuclein: The interplay of pathology, neuroinflammation, and environmental factors in Parkinson\u2019s disease. Neurodegener Dis 20(2\u20133):55\u201364","journal-title":"Neurodegener Dis"},{"key":"4720_CR46","doi-asserted-by":"publisher","first-page":"106314","DOI":"10.1016\/j.nbd.2023.106314","volume":"187","author":"X Xu","year":"2023","unstructured":"Xu X, Sun B, Zhao C (2023) Poly (ADP-Ribose) polymerase 1 and parthanatos in neurological diseases: from pathogenesis to therapeutic opportunities. Neurobiol Dis 187:106314","journal-title":"Neurobiol Dis"},{"key":"4720_CR47","doi-asserted-by":"crossref","unstructured":"Bogetofte H, et al (2020) Levodopa therapy for Parkinson\u2019s disease: history, current status and perspectives. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders) 19(8): 572\u2013583","DOI":"10.2174\/1871527319666200722153156"},{"key":"4720_CR48","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1007\/s10072-020-04333-5","volume":"41","author":"X Chen","year":"2020","unstructured":"Chen X et al (2020) Research advances on L-DOPA-induced dyskinesia: from animal models to human disease. Neurol Sci 41:2055\u20132065","journal-title":"Neurol Sci"},{"key":"4720_CR49","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2147\/JEP.S265282","volume":"13","author":"A Fabbrini","year":"2021","unstructured":"Fabbrini A, Guerra A (2021) Pathophysiological mechanisms and experimental pharmacotherapy for L-dopa-induced dyskinesia. J Exp Pharmacol 13:469\u2013485","journal-title":"J Exp Pharmacol"},{"key":"4720_CR50","doi-asserted-by":"publisher","first-page":"105429","DOI":"10.1016\/j.nbd.2021.105429","volume":"157","author":"L Andreoli","year":"2021","unstructured":"Andreoli L et al (2021) Distinct patterns of dyskinetic and dystonic features following D1 or D2 receptor stimulation in a mouse model of parkinsonism. Neurobiol Dis 157:105429","journal-title":"Neurobiol Dis"},{"key":"4720_CR51","doi-asserted-by":"publisher","first-page":"783893","DOI":"10.3389\/fnagi.2022.783893","volume":"14","author":"S Gao","year":"2022","unstructured":"Gao S et al (2022) Striatal D1 dopamine neuronal population dynamics in a rat model of levodopa-induced dyskinesia. Front Aging Neurosci 14:783893","journal-title":"Front Aging Neurosci"},{"key":"4720_CR52","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1016\/S1353-8020(09)70783-7","volume":"15","author":"C Guigoni","year":"2009","unstructured":"Guigoni C, Bezard E (2009) Involvement of canonical and non-canonical D1 dopamine receptor signalling pathways in L-dopa-induced dyskinesia. Parkinsonism Relat Disord 15:S64\u2013S67","journal-title":"Parkinsonism Relat Disord"},{"key":"4720_CR53","doi-asserted-by":"publisher","unstructured":"Song L, et al (2016) Targeting the D1-N-methyl-D-aspartate receptor complex reduces L-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson\u2019s rats. Drug Des Dev Ther 547\u2013555. https:\/\/doi.org\/10.2147\/DDDT.S93487","DOI":"10.2147\/DDDT.S93487"},{"key":"4720_CR54","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3389\/fnbeh.2011.00071","volume":"5","author":"M Feyder","year":"2011","unstructured":"Feyder M, Bonito-Oliva A, Fisone G (2011) L-DOPA-induced dyskinesia and abnormal signaling in striatal medium spiny neurons: focus on dopamine D1 receptor-mediated transmission. Front Behav Neurosci 5:71","journal-title":"Front Behav Neurosci"},{"key":"4720_CR55","doi-asserted-by":"publisher","first-page":"1253273","DOI":"10.3389\/fimmu.2023.1253273","volume":"14","author":"F Zhang","year":"2023","unstructured":"Zhang F et al (2023) Levodopa-induced dyskinesia: interplay between the N-methyl-D-aspartic acid receptor and neuroinflammation. Front Immunol 14:1253273","journal-title":"Front Immunol"},{"issue":"11","key":"4720_CR56","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1172\/JCI59426","volume":"122","author":"G Porras","year":"2012","unstructured":"Porras G et al (2012) PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking. J Clin Investig 122(11):3977\u20133989","journal-title":"J Clin Investig"},{"key":"4720_CR57","doi-asserted-by":"publisher","first-page":"805388","DOI":"10.3389\/fphar.2022.805388","volume":"13","author":"R Bandopadhyay","year":"2022","unstructured":"Bandopadhyay R et al (2022) Molecular mechanisms and therapeutic strategies for levodopa-induced dyskinesia in Parkinson\u2019s disease: a perspective through preclinical and clinical evidence. Front Pharmacol 13:805388","journal-title":"Front Pharmacol"},{"issue":"4","key":"4720_CR58","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1093\/brain\/awl031","volume":"129","author":"F Morgante","year":"2006","unstructured":"Morgante F et al (2006) Motor cortex plasticity in Parkinson\u2019s disease and levodopa-induced dyskinesias. Brain 129(4):1059\u20131069","journal-title":"Brain"},{"issue":"47","key":"4720_CR59","doi-asserted-by":"publisher","first-page":"16541","DOI":"10.1523\/JNEUROSCI.3047-12.2012","volume":"32","author":"P Halje","year":"2012","unstructured":"Halje P et al (2012) Levodopa-induced dyskinesia is strongly associated with resonant cortical oscillations. J Neurosci 32(47):16541\u201316551","journal-title":"J Neurosci"},{"issue":"4","key":"4720_CR60","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.4103\/NRR.NRR-D-23-01240","volume":"20","author":"P Wang","year":"2025","unstructured":"Wang P et al (2025) Cortico-striatal gamma oscillations are modulated by dopamine D3 receptors in dyskinetic rats. Neural Regen Res 20(4):1164\u20131177","journal-title":"Neural Regen Res"},{"issue":"4","key":"4720_CR61","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/ene.15234","volume":"29","author":"CC Wang","year":"2022","unstructured":"Wang CC et al (2022) Amantadine treatment and delayed onset of levodopa-induced dyskinesia in patients with early Parkinson\u2019s disease. Eur J Neurol 29(4):1044\u20131055","journal-title":"Eur J Neurol"},{"issue":"1","key":"4720_CR62","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/acn3.50961","volume":"7","author":"SY Fan","year":"2020","unstructured":"Fan SY et al (2020) Pallidal versus subthalamic nucleus deep brain stimulation for levodopa-induced dyskinesia. Ann Clin Transl Neurol 7(1):59\u201368","journal-title":"Ann Clin Transl Neurol"},{"issue":"5","key":"4720_CR63","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/syn.20500","volume":"62","author":"L Perrotti","year":"2008","unstructured":"Perrotti L et al (2008) Distinct patterns of \u0394FosB induction in brain by drugs of abuse. Synapse 62(5):358\u2013369","journal-title":"Synapse"},{"issue":"21","key":"4720_CR64","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1101\/gad.187900","volume":"14","author":"A Fleischmann","year":"2000","unstructured":"Fleischmann A et al (2000) Fra-1 replaces c-Fos-dependent functions in mice. Genes Dev 14(21):2695\u20132700","journal-title":"Genes Dev"},{"issue":"4","key":"4720_CR65","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/ijc.24807","volume":"126","author":"A Mishra","year":"2010","unstructured":"Mishra A et al (2010) Transactivation and expression patterns of Jun and Fos\/AP-1 super-family proteins in human oral cancer. Int J Cancer 126(4):819\u2013829","journal-title":"Int J Cancer"},{"issue":"13","key":"4720_CR66","doi-asserted-by":"publisher","first-page":"4933","DOI":"10.1523\/JNEUROSCI.17-13-04933.1997","volume":"17","author":"J Chen","year":"1997","unstructured":"Chen J et al (1997) Chronic Fos-related antigens: stable variants of \u0394FosB induced in brain by chronic treatments. J Neurosci 17(13):4933\u20134941","journal-title":"J Neurosci"},{"issue":"19","key":"4720_CR67","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.1523\/JNEUROSCI.4970-05.2006","volume":"26","author":"PG Ulery","year":"2006","unstructured":"Ulery PG, Rudenko G, Nestler EJ (2006) Regulation of \u0394FosB stability by phosphorylation. J Neurosci 26(19):5131\u20135142","journal-title":"J Neurosci"},{"key":"4720_CR68","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1111\/j.1460-9568.2007.05575.x","volume":"25","author":"T Carle","year":"2007","unstructured":"Carle T (2007) Absence of conserved C-terminal degron domain contributes to \u0394FosB\u2019s unique stability. Eur J Neurosci 25:3009","journal-title":"Eur J Neurosci"},{"issue":"1507","key":"4720_CR69","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1098\/rstb.2008.0067","volume":"363","author":"EJ Nestler","year":"2008","unstructured":"Nestler EJ (2008) Transcriptional mechanisms of addiction: role of \u0394FosB. Philos Trans Royal Soc B: Biol Sci 363(1507):3245\u20133255","journal-title":"Philos Trans Royal Soc B: Biol Sci"},{"issue":"6","key":"4720_CR70","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3109\/00952990.2014.933840","volume":"40","author":"JK Ruffle","year":"2014","unstructured":"Ruffle JK (2014) Molecular neurobiology of addiction: what\u2019s all the (\u0394) FosB about? Am J Drug Alcohol Abuse 40(6):428\u2013437","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"11","key":"4720_CR71","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/nn1143","volume":"6","author":"CA McClung","year":"2003","unstructured":"McClung CA, Nestler EJ (2003) Regulation of gene expression and cocaine reward by CREB and \u0394FosB. Nat Neurosci 6(11):1208\u20131215","journal-title":"Nat Neurosci"},{"key":"4720_CR72","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.brainresbull.2021.10.001","volume":"177","author":"ID Salinas-Velarde","year":"2021","unstructured":"Salinas-Velarde ID et al (2021) Lower \u0394FosB expression in the dopaminergic system after stevia consumption in rats housed under environmental enrichment conditions. Brain Res Bull 177:172\u2013180","journal-title":"Brain Res Bull"},{"issue":"47","key":"4720_CR73","doi-asserted-by":"publisher","first-page":"10594","DOI":"10.1523\/JNEUROSCI.2542-04.2004","volume":"24","author":"LI Perrotti","year":"2004","unstructured":"Perrotti LI et al (2004) Induction of \u0394FosB in reward-related brain structures after chronic stress. J Neurosci 24(47):10594\u201310602","journal-title":"J Neurosci"},{"issue":"2","key":"4720_CR74","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.neuron.2005.09.023","volume":"48","author":"A Kumar","year":"2005","unstructured":"Kumar A et al (2005) Chromatin remodeling is a key mechanism underlying cocaine-induced plasticity in striatum. Neuron 48(2):303\u2013314","journal-title":"Neuron"},{"issue":"3","key":"4720_CR75","doi-asserted-by":"publisher","first-page":"136","DOI":"10.9758\/cpn.2012.10.3.136","volume":"10","author":"EJ Nestler","year":"2012","unstructured":"Nestler EJ (2012) Transcriptional mechanisms of drug addiction. Cli Psychopharmacol Neurosci 10(3):136","journal-title":"Cli Psychopharmacol Neurosci"},{"issue":"20","key":"4720_CR76","doi-asserted-by":"publisher","first-page":"11042","DOI":"10.1073\/pnas.191352698","volume":"98","author":"EJ Nestler","year":"2001","unstructured":"Nestler EJ, Barrot M, Self DW (2001) \u0394FosB: a sustained molecular switch for addiction. Proc Natl Acad Sci 98(20):11042\u201311046","journal-title":"Proc Natl Acad Sci"},{"issue":"39","key":"4720_CR77","doi-asserted-by":"publisher","first-page":"10497","DOI":"10.1523\/JNEUROSCI.2566-07.2007","volume":"27","author":"CA Winstanley","year":"2007","unstructured":"Winstanley CA et al (2007) \u0394FosB induction in orbitofrontal cortex mediates tolerance to cocaine-induced cognitive dysfunction. J Neurosci 27(39):10497\u201310507","journal-title":"J Neurosci"},{"issue":"297","key":"4720_CR78","first-page":"2","volume":"7","author":"M Seltenhammer","year":"2016","unstructured":"Seltenhammer M et al (2016) Accumulation of highly stable \u0394FosB-isoforms and its targets inside the reward system of chronic drug abusers-a source of dependence-memory and high relapse rate. J Addict Res Ther 7(297):2","journal-title":"J Addict Res Ther"},{"issue":"4","key":"4720_CR79","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1124\/mi.10.4.5","volume":"10","author":"I Maze","year":"2010","unstructured":"Maze I, Russo SJ (2010) Transcriptional mechanisms underlying addiction-related structural plasticity. Mol Interventions 10(4):219","journal-title":"Mol Interventions"},{"key":"4720_CR80","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4303\/jdar\/235651","volume":"2","author":"EJ Nestler","year":"2013","unstructured":"Nestler EJ (2013) \u0394FosB: a molecular switch for reward. J Drug Alcohol Res 2:25\u201335","journal-title":"J Drug Alcohol Res"},{"issue":"6","key":"4720_CR81","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/nn.2551","volume":"13","author":"V Vialou","year":"2010","unstructured":"Vialou V et al (2010) \u0394FosB in brain reward circuits mediates resilience to stress and antidepressant responses. Nat Neurosci 13(6):745\u2013752","journal-title":"Nat Neurosci"},{"issue":"1","key":"4720_CR82","doi-asserted-by":"publisher","first-page":"4484","DOI":"10.1038\/s41467-020-17825-x","volume":"11","author":"AL Eagle","year":"2020","unstructured":"Eagle AL et al (2020) Circuit-specific hippocampal \u0394FosB underlies resilience to stress-induced social avoidance. Nat Commun 11(1):4484","journal-title":"Nat Commun"},{"issue":"1","key":"4720_CR83","doi-asserted-by":"publisher","first-page":"6376","DOI":"10.1038\/s41467-022-33947-w","volume":"13","author":"PJ Lamothe-Molina","year":"2022","unstructured":"Lamothe-Molina PJ et al (2022) \u0394FosB accumulation in hippocampal granule cells drives cFos pattern separation during spatial learning. Nat Commun 13(1):6376","journal-title":"Nat Commun"},{"key":"4720_CR84","doi-asserted-by":"publisher","unstructured":"Franzelin A, et al (2024) Epigenetic repression of cFos supports sequential formation of distinct spatial memories. bioRxiv. 2024.02. 16.580703.\u00a0https:\/\/doi.org\/10.1101\/2024.02.16.580703","DOI":"10.1101\/2024.02.16.580703"},{"issue":"34","key":"4720_CR85","doi-asserted-by":"publisher","first-page":"11461","DOI":"10.1523\/JNEUROSCI.1611-14.2014","volume":"34","author":"HM Cates","year":"2014","unstructured":"Cates HM et al (2014) Threonine 149 phosphorylation enhances \u0394FosB transcriptional activity to control psychomotor responses to cocaine. J Neurosci 34(34):11461\u201311469","journal-title":"J Neurosci"},{"issue":"10","key":"4720_CR86","doi-asserted-by":"publisher","first-page":"4295","DOI":"10.1523\/JNEUROSCI.5192-12.2013","volume":"33","author":"AJ Robison","year":"2013","unstructured":"Robison AJ et al (2013) Behavioral and structural responses to chronic cocaine require a feedforward loop involving \u0394FosB and calcium\/calmodulin-dependent protein kinase II in the nucleus accumbens shell. J Neurosci 33(10):4295\u20134307","journal-title":"J Neurosci"},{"issue":"5","key":"4720_CR87","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/npp.2013.319","volume":"39","author":"A Robison","year":"2014","unstructured":"Robison A et al (2014) Fluoxetine epigenetically alters the CaMKII\u03b1 promoter in nucleus accumbens to regulate \u0394FosB binding and antidepressant effects. Neuropsychopharmacology 39(5):1178\u20131186","journal-title":"Neuropsychopharmacology"},{"key":"4720_CR88","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.neuropharm.2012.03.025","volume":"66","author":"MT Dell\u2019Anno","year":"2013","unstructured":"Dell\u2019Anno MT, Pallottino S, Fisone G (2013) mGlu5R promotes glutamate AMPA receptor phosphorylation via activation of PKA\/DARPP-32 signaling in striatopallidal medium spiny neurons. Neuropharmacology 66:179\u2013186","journal-title":"Neuropharmacology"},{"key":"4720_CR89","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3389\/fnbeh.2011.00056","volume":"5","author":"M Yger","year":"2011","unstructured":"Yger M, Girault J-A (2011) DARPP-32, jack of all trades\u2026 master of which? Front Behav Neurosci 5:56","journal-title":"Front Behav Neurosci"},{"issue":"3","key":"4720_CR90","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/14728222.2017.1279149","volume":"21","author":"A Nishi","year":"2017","unstructured":"Nishi A, Shuto T (2017) Potential for targeting dopamine\/DARPP-32 signaling in neuropsychiatric and neurodegenerative disorders. Expert Opin Ther Targets 21(3):259\u2013272","journal-title":"Expert Opin Ther Targets"},{"issue":"32","key":"4720_CR91","doi-asserted-by":"publisher","first-page":"53791","DOI":"10.18632\/oncotarget.17339","volume":"8","author":"H Wang","year":"2017","unstructured":"Wang H et al (2017) The involvement of DARPP-32 in the pathophysiology of schizophrenia. Oncotarget 8(32):53791","journal-title":"Oncotarget"},{"issue":"2","key":"4720_CR92","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.neuron.2018.10.018","volume":"100","author":"GH Diering","year":"2018","unstructured":"Diering GH, Huganir RL (2018) The AMPA receptor code of synaptic plasticity. Neuron 100(2):314\u2013329","journal-title":"Neuron"},{"issue":"21","key":"4720_CR93","doi-asserted-by":"publisher","first-page":"6712","DOI":"10.1073\/pnas.1507229112","volume":"112","author":"AM Toda","year":"2015","unstructured":"Toda AM, Huganir RL (2015) Regulation of AMPA receptor phosphorylation by the neuropeptide PACAP38. Proc Natl Acad Sci 112(21):6712\u20136717","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"4720_CR94","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.conb.2011.09.008","volume":"22","author":"W Lu","year":"2012","unstructured":"Lu W, Roche KW (2012) Posttranslational regulation of AMPA receptor trafficking and function. Curr Opin Neurobiol 22(3):470\u2013479","journal-title":"Curr Opin Neurobiol"},{"issue":"43","key":"4720_CR95","doi-asserted-by":"publisher","first-page":"E5883","DOI":"10.1073\/pnas.1518382112","volume":"112","author":"NK Hussain","year":"2015","unstructured":"Hussain NK et al (2015) Regulation of AMPA receptor subunit GluA1 surface expression by PAK3 phosphorylation. Proc Natl Acad Sci 112(43):E5883\u2013E5890","journal-title":"Proc Natl Acad Sci"},{"key":"4720_CR96","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/bs.apcsb.2015.10.004","volume":"103","author":"K Lee","year":"2016","unstructured":"Lee K et al (2016) AMPA receptors as therapeutic targets for neurological disorders. Adv Protein Chem Struct Biol 103:203\u2013261","journal-title":"Adv Protein Chem Struct Biol"},{"issue":"11","key":"4720_CR97","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/S1474-4422(10)70218-0","volume":"9","author":"P Calabresi","year":"2010","unstructured":"Calabresi P et al (2010) Levodopa-induced dyskinesias in patients with Parkinson\u2019s disease: filling the bench-to-bedside gap. Lancet Neurol 9(11):1106\u20131117","journal-title":"Lancet Neurol"},{"issue":"7","key":"4720_CR98","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/eurheartj\/ehr304","volume":"33","author":"U F\u00f6rstermann","year":"2012","unstructured":"F\u00f6rstermann U, Sessa WC (2012) Nitric oxide synthases: regulation and function. Eur Heart J 33(7):829\u2013837","journal-title":"Eur Heart J"},{"issue":"11","key":"4720_CR99","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1111\/j.1460-9568.2008.06285.x","volume":"27","author":"J Garthwaite","year":"2008","unstructured":"Garthwaite J (2008) Concepts of neural nitric oxide-mediated transmission. Eur J Neurosci 27(11):2783\u20132802","journal-title":"Eur J Neurosci"},{"key":"4720_CR100","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s00424-009-0773-9","volume":"459","author":"Y Gao","year":"2010","unstructured":"Gao Y (2010) The multiple actions of NO. Pfl\u00fcgers Archiv-European J Physiol 459:829\u2013839","journal-title":"Pfl\u00fcgers Archiv-European J Physiol"},{"issue":"1\u20133","key":"4720_CR101","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ejphar.2012.03.008","volume":"683","author":"K Takuma","year":"2012","unstructured":"Takuma K et al (2012) Neuronal nitric oxide synthase inhibition attenuates the development of L-DOPA-induced dyskinesia in hemi-Parkinsonian rats. Eur J Pharmacol 683(1\u20133):166\u2013173","journal-title":"Eur J Pharmacol"},{"key":"4720_CR102","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.neuropharm.2014.08.019","volume":"89","author":"FE Padovan-Neto","year":"2015","unstructured":"Padovan-Neto FE et al (2015) Effects of prolonged neuronal nitric oxide synthase inhibition on the development and expression of L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats. Neuropharmacology 89:87\u201399","journal-title":"Neuropharmacology"},{"issue":"8","key":"4720_CR103","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1111\/febs.15908","volume":"289","author":"S Cataldi","year":"2022","unstructured":"Cataldi S et al (2022) Interpreting the role of the striatum during multiple phases of motor learning. FEBS J 289(8):2263\u20132281","journal-title":"FEBS J"},{"key":"4720_CR104","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00702-017-1744-5","volume":"125","author":"G Beck","year":"2018","unstructured":"Beck G, Singh A, Papa SM (2018) Dysregulation of striatal projection neurons in Parkinson\u2019s disease. J Neural Transm 125:449\u2013460","journal-title":"J Neural Transm"},{"issue":"1","key":"4720_CR105","doi-asserted-by":"publisher","first-page":"10068","DOI":"10.1038\/s41598-018-28273-5","volume":"8","author":"T Fieblinger","year":"2018","unstructured":"Fieblinger T et al (2018) Striatonigral neurons divide into two distinct morphological-physiological phenotypes after chronic L-DOPA treatment in parkinsonian rats. Sci Rep 8(1):10068","journal-title":"Sci Rep"},{"issue":"4","key":"4720_CR106","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/jnc.14558","volume":"147","author":"S Scheggi","year":"2018","unstructured":"Scheggi S, De Montis MG, Gambarana C (2018) DARPP-32 in the orchestration of responses to positive natural stimuli. J Neurochem 147(4):439\u2013453","journal-title":"J Neurochem"},{"issue":"2","key":"4720_CR107","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.phrs.2012.04.005","volume":"66","author":"R Roskoski Jr","year":"2012","unstructured":"Roskoski R Jr (2012) ERK1\/2 MAP kinases: structure, function, and regulation. Pharmacol Res 66(2):105\u2013143","journal-title":"Pharmacol Res"},{"key":"4720_CR108","doi-asserted-by":"publisher","first-page":"119499","DOI":"10.1016\/j.lfs.2021.119499","volume":"278","author":"ER Asl","year":"2021","unstructured":"Asl ER et al (2021) Interplay between MAPK\/ERK signaling pathway and MicroRNAs: a crucial mechanism regulating cancer cell metabolism and tumor progression. Life Sci 278:119499","journal-title":"Life Sci"},{"issue":"8","key":"4720_CR109","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/j.biotechadv.2013.08.017","volume":"31","author":"BC Heng","year":"2013","unstructured":"Heng BC, Aubel D, Fussenegger M (2013) An overview of the diverse roles of G-protein coupled receptors (GPCRs) in the pathophysiology of various human diseases. Biotechnol Adv 31(8):1676\u20131694","journal-title":"Biotechnol Adv"},{"issue":"5","key":"4720_CR110","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.3390\/cells10051228","volume":"10","author":"T Boczek","year":"2021","unstructured":"Boczek T et al (2021) The role of G protein-coupled receptors (GPCRs) and calcium signaling in schizophrenia. Focus on GPCRs activated by neurotransmitters and chemokines. Cells 10(5):1228","journal-title":"Cells"},{"key":"4720_CR111","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.cellsig.2017.01.024","volume":"41","author":"S Rajagopal","year":"2018","unstructured":"Rajagopal S, Shenoy SK (2018) GPCR desensitization: acute and prolonged phases. Cell Signal 41:9\u201316","journal-title":"Cell Signal"},{"issue":"1","key":"4720_CR112","doi-asserted-by":"publisher","first-page":"10920","DOI":"10.1038\/srep10920","volume":"5","author":"MR Ahmed","year":"2015","unstructured":"Ahmed MR et al (2015) GRK3 suppresses L-DOPA-induced dyskinesia in the rat model of Parkinson\u2019s disease via its RGS homology domain. Sci Rep 5(1):10920","journal-title":"Sci Rep"},{"key":"4720_CR113","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.neurobiolaging.2019.06.004","volume":"81","author":"MR Ahmed","year":"2019","unstructured":"Ahmed MR et al (2019) Pharmacological antagonism of histamine H2R ameliorated L-DOPA\u2013induced dyskinesia via normalization of GRK3 and by suppressing FosB and ERK in PD. Neurobiol Aging 81:177\u2013189","journal-title":"Neurobiol Aging"},{"issue":"1","key":"4720_CR114","first-page":"1","volume":"4","author":"\u0130 Otrav","year":"2023","unstructured":"Otrav \u0130, G\u00fcnal AM (2023) Effects of 5-hydroxytryptophan (5-Htp) nutritional supplement on health. J Innov Healthcare Pract 4(1):1\u20138","journal-title":"J Innov Healthcare Pract"},{"key":"4720_CR115","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3389\/fnmol.2018.00255","volume":"11","author":"H Wang","year":"2018","unstructured":"Wang H et al (2018) cAMP response element-binding protein (CREB): a possible signaling molecule link in the pathophysiology of schizophrenia. Front Mol Neurosci 11:255","journal-title":"Front Mol Neurosci"},{"issue":"1","key":"4720_CR116","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00726-001-0116-4","volume":"23","author":"M Cenci","year":"2002","unstructured":"Cenci M (2002) Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson\u2019s disease. Amino Acids 23(1):105\u2013109","journal-title":"Amino Acids"},{"key":"4720_CR117","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s11596-006-0514-7","volume":"26","author":"Z Chen","year":"2006","unstructured":"Chen Z et al (2006) Effect of antisense FosB and CREB on the expression of prodynorphin gene in rats with levodopa-induced dyskinesias. J Huazhong Univ Sci Technol 26:542\u2013544","journal-title":"J Huazhong Univ Sci Technol"},{"issue":"4","key":"4720_CR118","doi-asserted-by":"publisher","first-page":"402","DOI":"10.4062\/biomolther.2022.141","volume":"31","author":"Y Choi","year":"2023","unstructured":"Choi Y et al (2023) 5-Hydroxytryptophan reduces levodopa-induced dyskinesia via regulating AKT\/mTOR\/S6K and CREB\/\u0394FosB signals in a mouse model of Parkinson\u2019s disease. Biomol Ther 31(4):402","journal-title":"Biomol Ther"},{"issue":"4","key":"4720_CR119","doi-asserted-by":"publisher","first-page":"174","DOI":"10.5607\/en.2016.25.4.174","volume":"25","author":"H-Y Park","year":"2016","unstructured":"Park H-Y et al (2016) Palmitoyl serotonin inhibits L-dopa-induced abnormal involuntary movements in the mouse parkinson model. Exp Neurobiol 25(4):174","journal-title":"Exp Neurobiol"},{"issue":"5","key":"4720_CR120","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.3390\/molecules28052306","volume":"28","author":"FJ Mirza","year":"2023","unstructured":"Mirza FJ, Zahid S, Holsinger RD (2023) Neuroprotective effects of carnosic acid: insight into its mechanisms of action. Molecules 28(5):2306","journal-title":"Molecules"},{"key":"4720_CR121","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.nbd.2016.09.001","volume":"96","author":"I Sebastianutto","year":"2016","unstructured":"Sebastianutto I et al (2016) Validation of an improved scale for rating l-DOPA-induced dyskinesia in the mouse and effects of specific dopamine receptor antagonists. Neurobiol Dis 96:156\u2013170","journal-title":"Neurobiol Dis"},{"key":"4720_CR122","doi-asserted-by":"publisher","first-page":"703894","DOI":"10.3389\/fphar.2021.703894","volume":"12","author":"C-Y Lai","year":"2021","unstructured":"Lai C-Y et al (2021) Carnosic acid alleviates levodopa-induced dyskinesia and cell death in 6-hydroxydopamine-lesioned rats and in SH-SY5Y cells. Front Pharmacol 12:703894","journal-title":"Front Pharmacol"},{"issue":"35","key":"4720_CR123","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.1038\/onc.2008.120","volume":"27","author":"J Hernandez","year":"2008","unstructured":"Hernandez J et al (2008) Multiple facets of junD gene expression are atypical among AP-1 family members. Oncogene 27(35):4757\u20134767","journal-title":"Oncogene"},{"issue":"1","key":"4720_CR124","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.neuroscience.2006.09.001","volume":"144","author":"B Valastro","year":"2007","unstructured":"Valastro B et al (2007) Expression pattern of JunD after acute or chronic l-DOPA treatment: Comparison with \u0394FosB. Neuroscience 144(1):198\u2013207","journal-title":"Neuroscience"},{"issue":"7","key":"4720_CR125","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1021\/cn3000235","volume":"3","author":"Y Wang","year":"2012","unstructured":"Wang Y et al (2012) Small molecule screening identifies regulators of the transcription factor \u0394FosB. ACS Chem Neurosci 3(7):546\u2013556","journal-title":"ACS Chem Neurosci"},{"issue":"13","key":"4720_CR126","doi-asserted-by":"publisher","first-page":"6844","DOI":"10.1021\/cr400713r","volume":"114","author":"VN Uversky","year":"2014","unstructured":"Uversky VN et al (2014) Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases. Chem Rev 114(13):6844\u20136879","journal-title":"Chem Rev"},{"issue":"3","key":"4720_CR127","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s10787-022-00980-6","volume":"30","author":"A Hasanvand","year":"2022","unstructured":"Hasanvand A (2022) The role of AMPK-dependent pathways in cellular and molecular mechanisms of metformin: a new perspective for treatment and prevention of diseases. Inflammopharmacology 30(3):775\u2013788","journal-title":"Inflammopharmacology"},{"key":"4720_CR128","doi-asserted-by":"crossref","unstructured":"Kupsal K, et al (2016) Metformin combinatorial therapy for type 2 diabetes mellitus. J Metab Syndr 5(3): 2167\u20130943.1000210","DOI":"10.4172\/2167-0943.1000210"},{"key":"4720_CR129","doi-asserted-by":"publisher","first-page":"5715","DOI":"10.1007\/s12035-017-0752-7","volume":"55","author":"Y-K Ryu","year":"2018","unstructured":"Ryu Y-K et al (2018) Metformin inhibits the development of L-DOPA-induced dyskinesia in a murine model of Parkinson\u2019s disease. Mol Neurobiol 55:5715\u20135726","journal-title":"Mol Neurobiol"},{"issue":"4","key":"4720_CR130","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s11010-023-04771-7","volume":"479","author":"M Alrouji","year":"2024","unstructured":"Alrouji M et al (2024) Metformin role in Parkinson\u2019s disease: a double-sword effect. Mol Cell Biochem 479(4):975\u2013991","journal-title":"Mol Cell Biochem"},{"issue":"12","key":"4720_CR131","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3390\/cells7120278","volume":"7","author":"Y Chun","year":"2018","unstructured":"Chun Y, Kim J (2018) Autophagy: an essential degradation program for cellular homeostasis and life. Cells 7(12):278","journal-title":"Cells"},{"issue":"1","key":"4720_CR132","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/path.2697","volume":"221","author":"D Glick","year":"2010","unstructured":"Glick D, Barth S, Macleod KF (2010) Autophagy: cellular and molecular mechanisms. J Pathol 221(1):3\u201312","journal-title":"J Pathol"},{"key":"4720_CR133","first-page":"85","volume-title":"AMPK and autophagy","author":"Y Li","year":"2019","unstructured":"Li Y, Chen Y (2019) AMPK and autophagy. Basic Science, Autophagy Biology and Diseases, pp 85\u2013108"},{"issue":"1","key":"4720_CR134","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1146\/annurev-pharmtox-010611-134537","volume":"52","author":"K Inoki","year":"2012","unstructured":"Inoki K, Kim J, Guan K-L (2012) AMPK and mTOR in cellular energy homeostasis and drug targets. Annu Rev Pharmacol Toxicol 52(1):381\u2013400","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"12","key":"4720_CR135","doi-asserted-by":"publisher","first-page":"4444","DOI":"10.3390\/ijms21124444","volume":"21","author":"C Matrone","year":"2020","unstructured":"Matrone C et al (2020) Fyn tyrosine kinase as harmonizing factor in neuronal functions and dysfunctions. Int J Mol Sci 21(12):4444","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4720_CR136","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1742-4658.2011.08391.x","volume":"279","author":"CH Trepanier","year":"2012","unstructured":"Trepanier CH, Jackson MF, MacDonald JF (2012) Regulation of NMDA receptors by the tyrosine kinase Fyn. FEBS J 279(1):12\u201319","journal-title":"FEBS J"},{"issue":"27","key":"4720_CR137","doi-asserted-by":"publisher","first-page":"10058","DOI":"10.1523\/JNEUROSCI.0302-15.2015","volume":"35","author":"N Panicker","year":"2015","unstructured":"Panicker N et al (2015) Fyn kinase regulates microglial neuroinflammatory responses in cell culture and animal models of Parkinson\u2019s disease. J Neurosci 35(27):10058\u201310077","journal-title":"J Neurosci"},{"key":"4720_CR138","doi-asserted-by":"publisher","unstructured":"Bordone MP, et al (2021) Fyn knock-down prevents levodopa-induced dyskinesia in a mouse model of parkinson\u2019s disease. Eneuro 8(4). https:\/\/doi.org\/10.1523\/ENEURO.0559-20.2021","DOI":"10.1523\/ENEURO.0559-20.2021"},{"key":"4720_CR139","doi-asserted-by":"publisher","first-page":"105410","DOI":"10.1016\/j.nbd.2021.105410","volume":"156","author":"S Sharma","year":"2021","unstructured":"Sharma S et al (2021) Mechanisms of disease-modifying effect of saracatinib (AZD0530), a Src\/Fyn tyrosine kinase inhibitor, in the rat kainate model of temporal lobe epilepsy. Neurobiol Dis 156:105410","journal-title":"Neurobiol Dis"},{"key":"4720_CR140","doi-asserted-by":"publisher","first-page":"5125","DOI":"10.1007\/s12035-017-0748-3","volume":"55","author":"S Sanz-Blasco","year":"2018","unstructured":"Sanz-Blasco S et al (2018) The kinase Fyn as a novel intermediate in L-DOPA-induced dyskinesia in Parkinson\u2019s disease. Mol Neurobiol 55:5125\u20135136","journal-title":"Mol Neurobiol"},{"key":"4720_CR141","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s11064-010-0133-3","volume":"35","author":"SJ Na","year":"2010","unstructured":"Na SJ et al (2010) Molecular profiling of a 6-hydroxydopamine model of Parkinson\u2019s disease. Neurochem Res 35:761\u2013772","journal-title":"Neurochem Res"},{"key":"4720_CR142","doi-asserted-by":"publisher","unstructured":"Kaczy\u0144ska K, Andrzejewski K (2020) 6-hydroxydopamine-induced model of Parkinson\u2019s disease. Genetics, neurology, behavior, and diet in Parkinson\u2019s disease 627\u2013642. https:\/\/doi.org\/10.1016\/B978-0-12-815950-7.00040-0","DOI":"10.1016\/B978-0-12-815950-7.00040-0"},{"issue":"2","key":"4720_CR143","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.neulet.2011.06.021","volume":"500","author":"N Haleagrahara","year":"2011","unstructured":"Haleagrahara N et al (2011) Neuroprotective effect of bioflavonoid quercetin in 6-hydroxydopamine-induced oxidative stress biomarkers in the rat striatum. Neurosci Lett 500(2):139\u2013143","journal-title":"Neurosci Lett"},{"issue":"8","key":"4720_CR144","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.nrleng.2015.06.019","volume":"32","author":"D Hernandez-Baltazar","year":"2017","unstructured":"Hernandez-Baltazar D, Zavala-Flores L, Villanueva-Olivo A (2017) The 6-hydroxydopamine model and parkinsonian pathophysiology: novel findings in an older model. Neurolog\u00eda (English Edition) 32(8):533\u2013539","journal-title":"Neurolog\u00eda (English Edition)"},{"issue":"8","key":"4720_CR145","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41583-019-0189-2","volume":"20","author":"J Cox","year":"2019","unstructured":"Cox J, Witten IB (2019) Striatal circuits for reward learning and decision-making. Nat Rev Neurosci 20(8):482\u2013494","journal-title":"Nat Rev Neurosci"},{"issue":"10291","key":"4720_CR146","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem BR, Okun MS, Klein C (2021) Parkinson\u2019s disease. The Lancet 397(10291):2284\u20132303","journal-title":"The Lancet"},{"issue":"1","key":"4720_CR147","first-page":"572743","volume":"2011","author":"PA MacDonald","year":"2011","unstructured":"MacDonald PA, Monchi O (2011) Differential effects of dopaminergic therapies on dorsal and ventral striatum in Parkinson\u2019 s disease: implications for cognitive function. Parkinson\u2019s Disease 2011(1):572743","journal-title":"Parkinson\u2019s Disease"},{"key":"4720_CR148","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.pnpbp.2017.10.022","volume":"81","author":"A Chagraoui","year":"2018","unstructured":"Chagraoui A et al (2018) The pathophysiological mechanisms of motivational deficits in Parkinson\u2019s disease. Prog Neuropsychopharmacol Biol Psychiatry 81:138\u2013152","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"12","key":"4720_CR149","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1111\/cns.13979","volume":"28","author":"L Chen","year":"2022","unstructured":"Chen L et al (2022) Altered functional connectivity of nucleus accumbens subregions associates with non-motor symptoms in Parkinson\u2019s disease. CNS Neurosci Ther 28(12):2308\u20132318","journal-title":"CNS Neurosci Ther"},{"key":"4720_CR150","doi-asserted-by":"crossref","unstructured":"Lima MMS, et al (2012) Motor and non-motor features of Parkinson\u2019s disease\u2013a review of clinical and experimental studies. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders) 11(4):439\u2013449","DOI":"10.2174\/187152712800792893"},{"issue":"1","key":"4720_CR151","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.bbr.2011.09.025","volume":"226","author":"GA Smith","year":"2012","unstructured":"Smith GA et al (2012) Unilateral nigrostriatal 6-hydroxydopamine lesions in mice II: predicting l-DOPA-induced dyskinesia. Behav Brain Res 226(1):281\u2013292","journal-title":"Behav Brain Res"},{"key":"4720_CR152","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.neuroscience.2015.04.021","volume":"298","author":"U Keber","year":"2015","unstructured":"Keber U et al (2015) Striatal tyrosine hydroxylase-positive neurons are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Neuroscience 298:302\u2013317","journal-title":"Neuroscience"},{"key":"4720_CR153","doi-asserted-by":"publisher","unstructured":"Xu W, Jiang X, Huang L (2019) RNA interference technology. Comprehensive biotechnology, 560. https:\/\/doi.org\/10.1016\/B978-0-444-64046-8.00282-2","DOI":"10.1016\/B978-0-444-64046-8.00282-2"},{"key":"4720_CR154","doi-asserted-by":"publisher","unstructured":"Lambeth LS, Smith CA (2013) Short hairpin RNA-mediated gene silencing. siRNA Design: Methods and Protocols, 205\u2013232. https:\/\/doi.org\/10.1007\/978-1-62703-119-6_12","DOI":"10.1007\/978-1-62703-119-6_12"},{"issue":"11","key":"4720_CR155","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/jgm.1513","volume":"12","author":"Y Nishikawa","year":"2010","unstructured":"Nishikawa Y, Sugiyama T (2010) A shRNA library constructed through the generation of loop-stem-loop DNA. J Gene Med 12(11):927\u2013933","journal-title":"J Gene Med"},{"issue":"12","key":"4720_CR156","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/s41434-021-00249-7","volume":"28","author":"G Beck","year":"2021","unstructured":"Beck G et al (2021) Striatal \u0394FosB gene suppression inhibits the development of abnormal involuntary movements induced by L-Dopa in rats. Gene Ther 28(12):760\u2013770","journal-title":"Gene Ther"},{"key":"4720_CR157","doi-asserted-by":"publisher","unstructured":"Li Y, et al (2023) Effect of Tiaoshen Changzhi acupuncture on behavior and striatum \u0394FosB in rats with levodopa-induced dyskinesias. Biotechnol Gen Eng Rev 1\u201315. https:\/\/doi.org\/10.1080\/02648725.2023.2204694","DOI":"10.1080\/02648725.2023.2204694"},{"issue":"2","key":"4720_CR158","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2174\/1570159X16666180302115032","volume":"17","author":"S Jamwal","year":"2019","unstructured":"Jamwal S, Kumar P (2019) Insight into the emerging role of striatal neurotransmitters in the pathophysiology of Parkinson\u2019s disease and Huntington\u2019s disease: a review. Curr Neuropharmacol 17(2):165\u2013175","journal-title":"Curr Neuropharmacol"},{"issue":"2","key":"4720_CR159","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.neures.2004.06.015","volume":"50","author":"K Takakusaki","year":"2004","unstructured":"Takakusaki K, Saitoh K, Harada H, Kashiwayanagi M (2004) Role of basal ganglia\u2013brainstem pathways in the control of motor behaviors. Neurosci Res 50(2):137\u2013151","journal-title":"Neurosci Res"},{"key":"4720_CR160","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3389\/fnagi.2014.00087","volume":"6","author":"A Benazzouz","year":"2014","unstructured":"Benazzouz A et al (2014) Involvement of dopamine loss in extrastriatal basal ganglia nuclei in the pathophysiology of Parkinson\u2019s disease. Front Aging Neurosci 6:87","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"4720_CR161","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3233\/JPD-2011-11068","volume":"1","author":"HS Lindgren","year":"2011","unstructured":"Lindgren HS et al (2011) Putaminal upregulation of FosB\/\u0394FosB-like immunoreactivity in Parkinson\u2019s disease patients with dyskinesia. J Parkinson\u2019s Dis 1(4):347\u2013357","journal-title":"J Parkinson\u2019s Dis"},{"key":"4720_CR162","doi-asserted-by":"crossref","unstructured":"Koya E, Margetts\u2010Smith G, Hope BT (2016) Daun02 inactivation of behaviorally activated Fos\u2010expressing neuronal ensembles. Curr Protocol Neurosci 76(1):8.36. 1\u20138.36. 17","DOI":"10.1002\/cpns.2"},{"issue":"5","key":"4720_CR163","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41583-020-0292-4","volume":"21","author":"H Hu","year":"2020","unstructured":"Hu H, Cui Y, Yang Y (2020) Circuits and functions of the lateral habenula in health and in disease. Nat Rev Neurosci 21(5):277\u2013295","journal-title":"Nat Rev Neurosci"},{"issue":"5","key":"4720_CR164","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.biopsych.2014.08.022","volume":"79","author":"MF Bastide","year":"2016","unstructured":"Bastide MF et al (2016) Inhibiting lateral habenula improves L-DOPA\u2013induced dyskinesia. Biol Psychiat 79(5):345\u2013353","journal-title":"Biol Psychiat"},{"key":"4720_CR165","doi-asserted-by":"publisher","unstructured":"Arjmand S, et al (2024) Exploring the potential link between \u0394FosB and N-acetylcysteine in craving\/relapse dynamics: can N-acetylcysteine stand out as a possible treatment candidate?. Acta Neuropsychiatrica 1\u201314.\u00a0https:\/\/doi.org\/10.1017\/neu.2024.38","DOI":"10.1017\/neu.2024.38"},{"key":"4720_CR166","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.brainres.2007.01.069","volume":"1143","author":"IN Alibhai","year":"2007","unstructured":"Alibhai IN, Green TA, Potashkin JA, Nestler EJ (2007) Regulation of fosB and \u0394fosB mRNA expression: in vivo and in vitro studies. Brain Res 1143:22\u201333","journal-title":"Brain Res"},{"issue":"8","key":"4720_CR167","doi-asserted-by":"publisher","first-page":"e0160355","DOI":"10.1371\/journal.pone.0160355","volume":"11","author":"PA Gajewski","year":"2016","unstructured":"Gajewski PA, Turecki G, Robison AJ (2016) Differential expression of FosB proteins and potential target genes in select brain regions of addiction and depression patients. PLoS ONE 11(8):e0160355","journal-title":"PLoS ONE"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-04720-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-025-04720-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-04720-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:02:33Z","timestamp":1747195353000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-025-04720-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":167,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["4720"],"URL":"https:\/\/doi.org\/10.1007\/s12035-025-04720-z","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]},"assertion":[{"value":"13 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}